Span Divergent Ltd
₹ 34.9
0.00%
30 Mar
- close price
About
Incorporated in 1972, Span Divergent Ltd deals in different businesses through various subsidiaries.[1]
Key Points
- Market Cap ₹ 25.4 Cr.
- Current Price ₹ 34.9
- High / Low ₹ 35.2 / 19.0
- Stock P/E
- Book Value ₹ -5.57
- Dividend Yield 0.00 %
- ROCE -187 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -15.9%
- The company has delivered a poor sales growth of -0.91% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81.03 | 75.47 | 0.00 | 2.87 | 14.57 | 24.14 | 9.38 | 7.40 | 13.09 | 12.52 | 12.33 | 8.96 | 13.13 | |
| 77.14 | 74.28 | 5.23 | 8.37 | 25.16 | 31.34 | 15.16 | 9.64 | 12.67 | 11.42 | 10.94 | 9.61 | 15.81 | |
| Operating Profit | 3.89 | 1.19 | -5.23 | -5.50 | -10.59 | -7.20 | -5.78 | -2.24 | 0.42 | 1.10 | 1.39 | -0.65 | -2.68 |
| OPM % | 4.80% | 1.58% | -191.64% | -72.68% | -29.83% | -61.62% | -30.27% | 3.21% | 8.79% | 11.27% | -7.25% | -20.41% | |
| 0.55 | 53.94 | 9.98 | 4.04 | 2.57 | -0.76 | 1.96 | 0.82 | -7.54 | -3.45 | 1.77 | 1.25 | 1.81 | |
| Interest | 4.41 | 4.39 | 0.03 | 0.20 | 1.70 | 1.89 | 1.99 | 1.58 | 1.08 | 1.00 | 0.72 | 0.60 | 0.50 |
| Depreciation | 4.85 | 5.96 | 0.18 | 0.82 | 2.60 | 3.62 | 3.45 | 3.11 | 2.17 | 2.17 | 1.64 | 1.09 | 1.06 |
| Profit before tax | -4.82 | 44.78 | 4.54 | -2.48 | -12.32 | -13.47 | -9.26 | -6.11 | -10.37 | -5.52 | 0.80 | -1.09 | -2.43 |
| Tax % | 30.29% | 12.93% | 27.97% | 5.24% | 1.46% | 4.31% | -7.02% | 0.82% | -2.12% | -1.81% | 2.50% | 17.43% | |
| -6.28 | 38.99 | 3.28 | -2.61 | -12.50 | -14.05 | -8.61 | -6.16 | -10.15 | -5.42 | 0.79 | -1.28 | -2.51 | |
| EPS in Rs | -8.66 | 53.59 | 6.06 | -4.78 | -22.89 | -22.28 | -14.23 | -10.23 | -17.94 | -9.25 | 1.79 | -1.68 | -3.83 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -19% |
| 5 Years: | -1% |
| 3 Years: | -12% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 13% |
| 3 Years: | 4% |
| TTM: | -393% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 22% |
| 3 Years: | 36% |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.28 | 7.28 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 |
| Reserves | 15.35 | 54.41 | 44.71 | 43.11 | 30.61 | 19.87 | 12.12 | 6.56 | -3.24 | -8.30 | -7.35 | -8.27 | -8.50 |
| 37.52 | 0.34 | 0.19 | 13.12 | 23.18 | 22.30 | 19.19 | 17.99 | 13.19 | 11.15 | 9.11 | 8.36 | 7.34 | |
| 29.38 | 3.80 | 0.44 | 2.97 | 4.02 | 1.64 | 2.56 | 4.27 | 12.27 | 17.02 | 16.64 | 17.28 | 23.27 | |
| Total Liabilities | 89.53 | 65.83 | 50.80 | 64.66 | 63.27 | 49.27 | 39.33 | 34.28 | 27.68 | 25.33 | 23.86 | 22.83 | 27.57 |
| 41.26 | 2.20 | 2.15 | 8.15 | 25.91 | 22.47 | 20.19 | 17.72 | 15.36 | 13.12 | 10.75 | 9.64 | 9.87 | |
| CWIP | 1.75 | 0.09 | 0.06 | 10.95 | 0.00 | 0.06 | 0.13 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 45.81 | 35.55 | 27.87 | 25.50 | 16.36 | 10.07 | 9.43 | 4.03 | 3.95 | 4.69 | 6.30 | 5.43 |
| 46.52 | 17.73 | 13.04 | 17.69 | 11.86 | 10.38 | 8.94 | 7.11 | 8.29 | 8.26 | 8.42 | 6.89 | 12.27 | |
| Total Assets | 89.53 | 65.83 | 50.80 | 64.66 | 63.27 | 49.27 | 39.33 | 34.28 | 27.68 | 25.33 | 23.86 | 22.83 | 27.57 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.21 | 60.91 | -7.36 | -5.38 | -11.74 | -7.09 | -0.12 | -0.21 | 7.03 | 1.98 | 2.50 | 1.86 | |
| -4.80 | -12.13 | 13.39 | -5.55 | 0.81 | 10.05 | 5.89 | 1.99 | -2.05 | 0.53 | 0.12 | -1.05 | |
| -3.90 | -42.19 | -12.17 | 12.74 | 7.37 | -2.82 | -7.32 | -1.41 | -5.50 | -2.30 | -2.09 | -1.15 | |
| Net Cash Flow | -0.49 | 6.59 | -6.13 | 1.80 | -3.57 | 0.14 | -1.55 | 0.37 | -0.52 | 0.20 | 0.53 | -0.34 |
| Free Cash Flow | 3.99 | 47.54 | 3.91 | -21.44 | -15.13 | -6.93 | -1.46 | 1.79 | 8.12 | 1.85 | 2.12 | 1.91 |
| CFO/OP | 232% | 5,865% | 102% | 13% | 60% | 97% | -0% | 3% | 1,717% | 185% | 183% | -185% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82.07 | 3.72 | 1.27 | 59.62 | 22.08 | 39.30 | 73.49 | 44.06 | 55.39 | 45.88 | 56.62 | |
| Inventory Days | 189.41 | 2.68 | 314.18 | 101.31 | 52.17 | 83.88 | 143.23 | 179.48 | 317.65 | 206.08 | 123.31 | |
| Days Payable | 116.44 | 1.17 | 78.54 | 39.95 | 12.44 | 79.35 | 298.01 | 213.76 | 526.78 | 480.26 | 426.66 | |
| Cash Conversion Cycle | 155.05 | 5.24 | 236.90 | 120.98 | 61.81 | 43.84 | -81.29 | 9.77 | -153.74 | -228.30 | -246.72 | |
| Working Capital Days | -68.69 | -7.01 | -705.84 | -228.22 | -185.98 | -310.52 | -400.02 | -428.58 | -599.98 | -608.63 | -930.83 | |
| ROCE % | -0.64% | -4.35% | -5.73% | -8.98% | -19.95% | -19.10% | -19.87% | -15.86% | -3.67% | -9.50% | 36.03% | -186.79% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees (Standalone) count ・Standalone data |
|
||||||||||
| Median Remuneration of Employees INR ・Standalone data |
|||||||||||
| Revenue by Segment - Cashew Processing INR Lacs |
|||||||||||
| Revenue by Segment - Tissue Culture INR Lacs |
|||||||||||
| Revenue by Segment - Trading (Life Sciences/Healthcare) INR Lacs |
|||||||||||
| Biological Asset Valuation (Tissue Culture) INR Lacs |
|||||||||||
Requires Premium
Requires Premium
Documents
Announcements
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 29m
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 1h
-
Announcement under Regulation 30 (LODR)-Preferential Issue
28 Mar - Allotment of 18,01,481 shares at Rs.32.16 to Mr. Neev N. Jogani; proceeds Rs.5.79 crore; allottee 24.80%.
-
Announcement under Regulation 30 (LODR)-Allotment
28 Mar - Allotment of 1,801,481 shares at Rs.32.16 to Neev Jogani; raises Rs.5.7936 crore; 24.8% stake.
-
Board Meeting Outcome for Span Divergent Limited - Outcome Of Board Meeting Held On March 28, 2026
28 Mar - Allotment of 18,01,481 shares to Mr. Neev Jogani at Rs32.16; proceeds Rs5.79 crore; allottee 24.80%.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
SDL operates across multiple business segments through dedicated subsidiaries in the Food, Agriculture, and Life Sciences verticals. It also provides management consulting and support services, offering financial, technical, and operational expertise to its group entities. The company actively oversees compliance, networking, and business development activities, while closely monitoring subsidiary performance and implementing strategic guidance and corrective measures as approved by the Board.